Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $52

Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $54 to $52.